Biotech | December 24, 2021
Novavax and SK bioscience expand manufacturing agreement
SK bioscience secures long-term license to supply the Novavax vaccine for the Korean market
SK bioscience secures long-term license to supply the Novavax vaccine for the Korean market
SAGE recommends additional third dose of the vaccine administered to immunocompromised persons
The vaccine will be manufactured and marketed in the Philippines by SII under the brand name Covovax
All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for WHO
The vaccine can be stored at 2 to 8 degrees celsius and traditional cold chain capabilities will suffice
Filing marks first protein-based vaccine submitted to MHRA for authorization
It is a recombinant nanoparticle protein-based vaccine
Study to explore heterologous regimen of COVID-19 vaccines from different manufacturers in adolescents 12-16 years of age
First participants enrolled in Phase 1 clinical trial of combination NanoFlu/NVX-CoV2373 vaccine with Matrix-M adjuvant. The Phase 1/2 study will also evaluate immunogenicity and safety
Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)